Literature DB >> 3192639

Assessment of the arterial input curve for [99mTc]-d,l-HM-PAO by rapid octanol extraction.

A R Andersen1, H Friberg, N A Lassen, K Kristensen, R D Neirinckx.   

Abstract

The in vitro conversion of the lipophilic molecule [99mTc]-d,l-hexamethylpropyleneamine oxime [( 99mTc]-d,l-HM-PAO) to a hydrophilic form was studied in saline, plasma, and blood at 37 degrees C by paper chromatography and by octanol extraction. The octanol:saline ratio was 79.9. From this value and the corresponding octanol: plasma and octanol:blood partitioning values, an estimate of the transport of the lipophilic compound by various components of blood was made: 20% is carried in hemoglobin, 53% by the plasma proteins and 27% by the water phases of the red blood cell and plasma. Octanol extraction provided a rapid method for measuring the radiochemical purity (RCP) of lipophilic [99mTc]-d,l-HM-PAO. In saline, the RCP declined with a half-life of more than 1 h. In human plasma and whole blood, the conversion of [99mTc]-d,l-HM-PAO was biexponential due to the differences in the conversion rates of the d and l isomeric forms. The initial half-life representing the conversion rate of the l form was 1.7 min in blood and 1.4 min in plasma, while the conversion half-life of the d form was 7.4 and 24.4 min, respectively. In vivo, the RCP of arterial blood sampled after an i.v. bolus injection showed an initial peak value of 75% (68-79%) during the initial, first passage of the bolus. It declined to approximately 35% (29-40%) after 1.5 min and reached very low levels (about 1%) at 6 to 10 min. Quantitative measurements of cerebral blood flow using [99mTc]-d,l-HM-PAO necessitates a rapid method for RCP determination in arterial blood such as the one described here.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3192639     DOI: 10.1038/jcbfm.1988.29

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  6 in total

1.  A quantitative approach to technetium-99m hexamethylpropylene amine oxime.

Authors:  H Matsuda; S Tsuji; N Shuke; H Sumiya; N Tonami; K Hisada
Journal:  Eur J Nucl Med       Date:  1992

2.  Required time delay from 99mTc-HMPAO injection to SPECT data acquisition: healthy subjects and patients with rCBF pattern.

Authors:  Gerda Thomsen; Robin de Nijs; Esben Hogh-Rasmussen; Vibe Frokjaer; Claus Svarer; Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-10       Impact factor: 9.236

3.  In vivo metabolism and kinetics of 99mTc-HMPAO.

Authors:  G Lucignani; C Rossetti; P Ferrario; L Zecca; M C Gilardi; F Zito; D Perani; G L Lenzi; F Fazio
Journal:  Eur J Nucl Med       Date:  1990

4.  Role of glutathione in lung retention of 99mTc-hexamethylpropyleneamine oxime in two unique rat models of hyperoxic lung injury.

Authors:  Said H Audi; David L Roerig; Steven T Haworth; Anne V Clough
Journal:  J Appl Physiol (1985)       Date:  2012-05-24

5.  Pharmacokinetics of 99mTc-HMPAO in isolated perfused rat lungs.

Authors:  Anne V Clough; Katherine Barry; Benjamin M Rizzo; Elizabeth R Jacobs; Said H Audi
Journal:  J Appl Physiol (1985)       Date:  2019-08-15

6.  Quantitative comparison between 99mTc-HMPAO and 99mTc-ECD: measurement of arterial input and brain retention.

Authors:  A Pupi; A Castagnoli; M T De Cristofaro; L Bacciottini; A R Petti
Journal:  Eur J Nucl Med       Date:  1994-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.